title: SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
abstract: Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.
authors.affiliation: Department of Medical Oncology, Complejo Hospitalario de Navarra, c/Irunlarrea-3, 31008, Pamplona, Spain. rveragar@cfnavarra.es.
authors.forename: R
authors.initials: R
authors.lastname: Vera
authors.affiliation: Consorcio Sanitario de Terrassa, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Dotor
authors.affiliation: Hospital Universitario la Paz, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Feliu
authors.affiliation: Complejo Hospitalario Universitario de Granada Virgen de las Nieves, Granada, Spain.
authors.forename: E
authors.initials: E
authors.lastname: González
authors.affiliation: ICO-Hospitalet de LLobregat, Hospital Duran i Reynals, Hospitalet de Llobregat, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Laquente
authors.affiliation: Hospital Vall`Hebron, Barcelona, Spain.
authors.forename: T
authors.initials: T
authors.lastname: Macarulla
authors.affiliation: Hospital Universitario Marqués de Valdecilla, Santander, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Martínez
authors.affiliation: Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Maurel
authors.affiliation: Complexo Hospitalario de Orense (CHUO), Ourense, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Salgado
authors.affiliation: ICO-Badalona, Hospital Germans Trias i Pujol, Barcelona, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Manzano
mesh_terms: D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D013030:Spain; D016896:Treatment Outcome
keywords: Diagnostic; Guidelines; Pancreatic cancer; Treatment